XMD-17-51 Trifluoroacetate

XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that is able to modulate protein kinases.

Product information

Molecular Weight: 518.49

Formula: C23H25F3N8O3

Chemical Name: 2,9-dimethyl-5-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-2,4,6,9-tetraazatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-10-one; trifluoroacetic acid

Smiles: CN1C2=CC=CC=C2C(=O)N(C)C2=CN=C(NC3=CN(N=C3)C3CCNCC3)N=C12.OC(=O)C(F)(F)F

InChiKey: LCEQZCVFZRUKMK-UHFFFAOYSA-N

InChi: InChI=1S/C21H24N8O.C2HF3O2/c1-27-17-6-4-3-5-16(17)20(30)28(2)18-12-23-21(26-19(18)27)25-14-11-24-29(13-14)15-7-9-22-10-8-15;3-2(4,5)1(6)7/h3-6,11-13,15,22H,7-10H2,1-2H3,(H,23,25,26);(H,6,7)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 150 mg/mL (289.30 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that is able to modulate protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK, ULK2, PLK, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and can be used in the treatment of various diseases, disorders or conditions.

Products are for research use only. Not for human use.